- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 401/08 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
Patent holdings for IPC class C07D 401/08
Total number of patents in this class: 256
10-year publication summary
|
18
|
20
|
32
|
14
|
24
|
12
|
28
|
10
|
14
|
6
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Nxera Pharma UK Limited | 185 |
18 |
| Assembly Biosciences, Inc. | 103 |
10 |
| Pfizer Inc. | 3409 |
9 |
| Janssen Pharmaceutica N.V. | 3160 |
6 |
| Merck Patent GmbH | 5735 |
6 |
| Bristol-myers Squibb Company | 4757 |
5 |
| F. Hoffmann-La Roche AG | 7808 |
5 |
| Cytokinetics, Inc. | 251 |
5 |
| Karyopharm Therapeutics Inc. | 145 |
5 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 876 |
5 |
| Merck Sharp & Dohme LLC | 3737 |
5 |
| AstraZeneca AB | 2824 |
4 |
| Baylor College of Medicine | 1009 |
4 |
| Heptares Therapeutics Limited | 73 |
4 |
| Incyte Holdings Corporation | 626 |
4 |
| Taro Pharmaceuticals Inc. | 15 |
4 |
| Universite de Rouen | 98 |
4 |
| Takeda Pharmaceutical Company Limited | 2700 |
3 |
| Incyte Corporation | 1066 |
3 |
| Katholieke Universiteit Leuven | 1298 |
3 |
| Other owners | 144 |